Ticker Details
Zymeworks Inc. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
IPO Date:	April 28, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.99B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.52 | 2.96%
Avg Daily Range (30 D):	$0.54 | 2.21%
Avg Daily Range (90 D):	$0.72 | 3.08%

Institutional Daily Volume
Avg Daily Volume:	.46M
Avg Daily Volume (30 D):	.54M
Avg Daily Volume (90 D):	.54M

Trade Size
Avg Trade Size (Sh.):	94
Avg Trade Size (Sh.) (30 D):	52
Avg Trade Size (Sh.) (90 D):	47

Institutional Trades
Total Institutional Trades:	1,939
Avg Institutional Trade:	$1.83M
Avg Institutional Trade (30 D):	$3.16M
Avg Institutional Trade (90 D):	$2.69M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.57M
Avg Closing Trade (30 D):	$2.8M
Avg Closing Trade (90 D):	$2.61M
Avg Closing Volume:	100.15K

News

Jun 29, 2026 @ 10:00 AM Zymeworks to Acquire Theravance Biopharma, Inc. Source: Na

Jun 14, 2026 @ 10:05 PM Zymeworks Presents New Phase 1 Data for Folate Rec... Source: Zymeworks Inc.

May 13, 2026 @ 10:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: Na

Apr 17, 2026 @ 7:00 PM Zymeworks Presents New Preclinical Data at AACR 20... Source: Zymeworks Inc.

Apr 9, 2026 @ 10:00 AM Zymeworks Announces Additional Leadership Appointm... Source: Na

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.59	$-.55	$-1.08
Diluted EPS	$-.59	$-.55	$-1.08
Revenue	$2.41M	$2.52M	$105.97M
Gross Profit
Net Income / Loss	$-44.16M	$-41.21M	$-81.13M
Operating Income / Loss	$-47.12M	$-44.15M	$-92.55M
Cost of Revenue
Net Cash Flow	$203.13M	$-23.68M	$-24.95M
PE Ratio